-
1
-
-
52949090626
-
-
Colon and Rectum Cancer. March 7, Available at, Accessed June 30, 2006
-
American Cancer Society. Detailed Guide: Colon and Rectum Cancer. March 7, 2006. Available at http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=10. Accessed June 30, 2006.
-
(2006)
Detailed Guide
-
-
-
2
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
3
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
-
Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
-
4
-
-
0028939208
-
Measuring quality of life in palliative care
-
Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995;22(suppl 3):73-81.
-
(1995)
Semin Oncol
, vol.22
, Issue.SUPPL. 3
, pp. 73-81
-
-
Cella, D.F.1
-
5
-
-
52949120867
-
-
Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4. Evanston, IL: Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.
-
Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4. Evanston, IL: Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.
-
-
-
-
6
-
-
0032771187
-
Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument
-
Ward WL, Hahn EA, Mo F et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res 1999;8:181-195.
-
(1999)
Qual Life Res
, vol.8
, pp. 181-195
-
-
Ward, W.L.1
Hahn, E.A.2
Mo, F.3
-
7
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
-
(2000)
N Engl J Med
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
8
-
-
0024385167
-
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group
-
Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-1426.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1419-1426
-
-
Petrelli, N.1
Douglass Jr, H.O.2
Herrera, L.3
-
9
-
-
0036195669
-
Clinical Consensus Meeting Group. Methods to explain the clinical significance of health status measures
-
Guyatt GH, Osoba D, Wu AW et al.; Clinical Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-383.
-
(2002)
Mayo Clin Proc
, vol.77
, pp. 371-383
-
-
Guyatt, G.H.1
Osoba, D.2
Wu, A.W.3
-
10
-
-
0036184207
-
What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592
-
Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-295.
-
(2002)
J Clin Epidemiol
, vol.55
, pp. 285-295
-
-
Cella, D.1
Eton, D.T.2
Fairclough, D.L.3
-
11
-
-
0036964529
-
Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales
-
Cella D, Eton DT, Lai JS et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
-
(2002)
J Pain Symptom Manage
, vol.24
, pp. 547-561
-
-
Cella, D.1
Eton, D.T.2
Lai, J.S.3
-
12
-
-
0037304852
-
Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa
-
Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345.
-
(2003)
Eur J Cancer
, vol.39
, pp. 335-345
-
-
Patrick, D.L.1
Gagnon, D.D.2
Zagari, M.J.3
-
13
-
-
7044224362
-
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale
-
Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57:898-910.
-
(2004)
J Clin Epidemiol
, vol.57
, pp. 898-910
-
-
Eton, D.T.1
Cella, D.2
Yost, K.J.3
-
14
-
-
17744362659
-
Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
-
Yost KJ, Yount SE, Eton DT et al. Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat 2005;90:295-298.
-
(2005)
Breast Cancer Res Treat
, vol.90
, pp. 295-298
-
-
Yost, K.J.1
Yount, S.E.2
Eton, D.T.3
-
15
-
-
17144411798
-
Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument
-
Yost KJ, Sorensen MV, Hahn EA et al. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 2005;8:117-127.
-
(2005)
Value Health
, vol.8
, pp. 117-127
-
-
Yost, K.J.1
Sorensen, M.V.2
Hahn, E.A.3
-
16
-
-
27744526720
-
Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches
-
Yost KJ, Cella D, Chawla A et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol 2005;58:1241-1251.
-
(2005)
J Clin Epidemiol
, vol.58
, pp. 1241-1251
-
-
Yost, K.J.1
Cella, D.2
Chawla, A.3
-
17
-
-
0002429117
-
A confidence interval for the median survival time
-
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
-
(1982)
Biometrics
, vol.38
, pp. 29-41
-
-
Brookmeyer, R.1
Crowley, J.2
|